Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a medicare advantage prescription drug plan population

Journal of Managed Care Pharmacy

Volumn 19, Issue 5, 2013, Pages 374-384

  Bergeson, Joette Gdovin ^a   Worley, Karen ^b   Louder, Anthony ^b   Ward, Melea ^c   Graham, John ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Formerly of Comprehensive Health Insights Inc   (United States)

^c HUMANA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; EXENDIN 4; INSULIN; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIOR AUTHORIZATION;

EID: 84878968748     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.5.374     Document Type: Article

References (15)

1. Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6 Suppl):S3-S20. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8359.
2. Academy of Managed Care Pharmacy. Concepts in Managed Care Pharmacy: Prior Authorization. Concept Document. April, 2012. Available at: http://www.amcp.org/prior_authorization/. Accessed March 31, 2013.
3. Starner CI, Fenrick B, Coleman J, Wickersham P, Gleason PP. Rosiglitazone prior authorization safety policy: a cohort study. J Manag Care Pharm. 2012;18(3):225-33. Available at: http://www.amcp.org/JMCP/2012/April/14984/1033.html.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
6. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2003;41(1):84-99.
7. Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, Sharp ND. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacybased case-mix instrument. Med Care. 2003;41(6):761-74.
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
9. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict health care expenditures. Am J Manag Care. 2006;12(2):110-19.
10. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-88.
11. Vogt WB, Joyce G, Xia J, Dirani R, Wan G, Goldman DP. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Aff (Millwood). 2011;30(12):2346-54.
12. Lu CY, Law MR, Soumerai SB, et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population- based study. Clin Ther. 2011;33(1):135-44.
13. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15(10):e95-102.
14. Abouzaid S, Jutkowitz E, Foley KA, Pizzi LT, Kim E, Bates J. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag. 2010;13(5):247-54.
15. Kahan NR, Chinitz DP, Blackman S, Waitman DA, Vardy DA. Modifying prescribing behaviour of angiotensin receptor blockers by selectively rescinding managerial prior authorization requirements for losartan. Br J Clin Pharmacol. 2011;72(6):997-1001.